🇺🇸 FDA
Patent

US 12049630

Factor XII (F12) iRNA compositions and methods of use thereof

granted A61KA61K47/549

Quick answer

US patent 12049630 (Factor XII (F12) iRNA compositions and methods of use thereof) held by Alnylam Pharmaceuticals, Inc. expires Mon Jul 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Alnylam Pharmaceuticals, Inc.
Grant date
Tue Jul 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
30
CPC classes
A61K, A61K47/549